Skip to main content

Advertisement

Table 5 Incremental cost-effectiveness ratios, societal perspective, 0 to 6 months

From: Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial

  Incremental cost Incremental effect ICER
  Mean; (95% bootstrap CI) Mean; (95% bootstrap CI)
CBT versus TAU
Completers ( N =152)       
QALY (EQ-5D) -2,061.9 -3,168.9 -954.9 0.01 -0.00 0.03 CBT dominant
EQ VAS -2,073.2 -3,179.8 -966.6 6.19 3.63 8.75 CBT dominant
ITT ( N =168)        
QALY (EQ-5D) -2,158.8 -3,357.1 -960.5 0.02 -0.00 0.03 CBT dominant
EQ VAS -2,163.9 -3,363.8 -964.0 6.33 3.62 9.07 CBT dominant
PPA ( N =154)       
QALY (EQ-5D) -2,368.9 -3,599.1 -1,138.6 0.02 -0.00 0.03 CBT dominant
EQ VAS -2,372.4 -3,604.8 -1,140.0 6.58 3.83 9.33 CBT dominant
CBT versus RPT
Completers ( N =152)       
QALY (EQ-5D) -2,386.9 -3,485.4 -1,288.3 0.01 -0.00 0.03 CBT dominant
EQ VAS -2,393.9 -3,495.2 -1,292.6 3.52 1.13 5.90 CBT dominant
ITT ( N =168)        
QALY (EQ-5D) -2,304.7 -3,326.6 -1,282.7 0.01 -0.00 0.03 CBT dominant
EQ VAS -2,307.8 -3,331.4 -1,284.2 3.61 1.08 6.15 CBT dominant
PPA ( N =154)       
QALY (EQ-5D) -2,550.3 -3,624.9 -1,475.7 0.01 -0.00 0.03 CBT dominant
EQ VAS -2,552.7 -3,631.5 -1,473.9 3.93 1.35 6.51 CBT dominant
RPT versus TAU
Completers ( N =152)        
QALY (EQ-5D) 324.9 -894.8 1,544.7 -0.00 -0.02 0.01 TAU dominant
EQ VAS 320.7 -894.3 1,535.6 2.67 0.56 4.79 120
ITT ( N =168)        
QALY (EQ-5D) 145.9 -1,150.7 1,442.5 0.00 -0.01 0.02 79,071
EQ VAS 143.9 -1,150.8 1,438.6 2.72 0.42 5.02 53
PPA ( N =154)       
QALY (EQ-5D) 181.4 -1,127.9 1,490.7 0.00 -0.01 0.02 137,161
EQ VAS 180.3 -1,127.3 1,487.9 2.65 0.36 4.94 68